AbbVie and Xilio Therapeutics have announced a partnership worth over $2.1bn to develop tumour-activated, antibody-based immunotherapies. The collaboration and option-to-licence agreement will include ...
RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...
AbbVie has entered a partnership and option-to-license agreement with Xilio Therapeutics to develop new tumour-activated, ...
The Dow Jones index dropped 400 points on Wednesday, February 12 as US Inflation data dimmed Federal Reserve rate cuts hopes ...
Stock Market Today saw a sharp decline as the Dow Jones plummeted 400 points following a rise in US Inflation to 3% YoY. The ...
Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...
AbbVie and Xilio Therapeutics are partnering to make “masked” T cell engagers, which they hope will be safer than currently available options.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback